SI2945620T1 - Nitroxyl donors with improved therapeutic index - Google Patents

Nitroxyl donors with improved therapeutic index Download PDF

Info

Publication number
SI2945620T1
SI2945620T1 SI201430507T SI201430507T SI2945620T1 SI 2945620 T1 SI2945620 T1 SI 2945620T1 SI 201430507 T SI201430507 T SI 201430507T SI 201430507 T SI201430507 T SI 201430507T SI 2945620 T1 SI2945620 T1 SI 2945620T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical composition
compound
formula
composition according
administered intravenously
Prior art date
Application number
SI201430507T
Other languages
English (en)
Slovenian (sl)
Inventor
Vincent Jacob Kalish
Frederick Arthur Brookfield
Stephen Martin Courtney
Lisa Marie Frost
John P. Toscano
Original Assignee
Cardioxyl Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc. filed Critical Cardioxyl Pharmaceuticals Inc.
Publication of SI2945620T1 publication Critical patent/SI2945620T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201430507T 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index SI2945620T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US201361782781P 2013-03-14 2013-03-14
PCT/US2014/012085 WO2014113696A1 (en) 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index
EP14703009.2A EP2945620B1 (en) 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index

Publications (1)

Publication Number Publication Date
SI2945620T1 true SI2945620T1 (en) 2018-01-31

Family

ID=50064795

Family Applications (3)

Application Number Title Priority Date Filing Date
SI201430507T SI2945620T1 (en) 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index
SI201431361T SI3284463T1 (sl) 2013-01-18 2014-01-17 Donorji nitroksila z izboljšanim terapevtskim indeksom
SI201430983T SI2945621T1 (sl) 2013-01-18 2014-01-17 Farmacevtski sestavki, ki vsebujejo nitroksilne donatorje

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI201431361T SI3284463T1 (sl) 2013-01-18 2014-01-17 Donorji nitroksila z izboljšanim terapevtskim indeksom
SI201430983T SI2945621T1 (sl) 2013-01-18 2014-01-17 Farmacevtski sestavki, ki vsebujejo nitroksilne donatorje

Country Status (29)

Country Link
US (13) US8987326B2 (OSRAM)
EP (5) EP3427728B1 (OSRAM)
JP (5) JP6533159B2 (OSRAM)
KR (2) KR102277165B1 (OSRAM)
CN (4) CN108610312A (OSRAM)
AU (5) AU2014207408C1 (OSRAM)
BR (2) BR112015017251B1 (OSRAM)
CA (2) CA2898443C (OSRAM)
CY (3) CY1120535T1 (OSRAM)
DK (3) DK3284463T3 (OSRAM)
ES (4) ES2882279T3 (OSRAM)
HK (1) HK1251170B (OSRAM)
HR (3) HRP20182144T1 (OSRAM)
HU (3) HUE036589T2 (OSRAM)
IL (4) IL239906B (OSRAM)
LT (3) LT3284463T (OSRAM)
MX (2) MX363843B (OSRAM)
NZ (4) NZ748769A (OSRAM)
PL (3) PL3284463T3 (OSRAM)
PT (3) PT3284463T (OSRAM)
RS (3) RS58174B1 (OSRAM)
RU (3) RU2684916C2 (OSRAM)
SG (6) SG10201802855TA (OSRAM)
SI (3) SI2945620T1 (OSRAM)
SM (3) SMT201800088T1 (OSRAM)
TR (1) TR201802211T4 (OSRAM)
TW (3) TWI619491B (OSRAM)
WO (2) WO2014113696A1 (OSRAM)
ZA (2) ZA201505090B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595770A (en) 2006-03-17 2013-04-26 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
BR112014009282B1 (pt) 2011-10-17 2021-12-14 The Johns Hopkins University Composto, composição farmacêutica contendo-o e uso do mesmo
HRP20182144T1 (hr) 2013-01-18 2019-03-08 Cardioxyl Pharmaceuticals Inc. Farmaceutske kompozicije koje sadrže donore nitroksila
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2017041701A1 (zh) 2015-09-07 2017-03-16 浙江华海药业股份有限公司 可释放一氧化氮的前药分子
US10730828B2 (en) 2015-10-19 2020-08-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
WO2017070081A1 (en) 2015-10-19 2017-04-27 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
CN110139854A (zh) 2016-07-28 2019-08-16 约翰斯霍普金斯大学 O-取代异羟肟酸
KR20190103281A (ko) * 2017-01-03 2019-09-04 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여 화합물의 투여 방법
AU2018253885B2 (en) * 2017-04-18 2024-04-11 Genfit Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
CN116283762B (zh) * 2023-03-28 2025-08-12 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
CA2181581A1 (en) * 1994-01-19 1995-07-20 Jan Bron Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
KR20010031319A (ko) 1997-10-24 2001-04-16 요시히코 시오노 항류마티스제
SI0930302T1 (en) * 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
AU4333799A (en) 1998-06-04 1999-12-20 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
KR100501022B1 (ko) 1998-07-28 2005-07-18 다나베 세이야꾸 가부시키가이샤 장내 적소 방출형 제제
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
ES2267853T3 (es) * 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2005074598A2 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
EP1909779A1 (en) 2005-06-23 2008-04-16 Johns Hopkins University Thiol-sensitive positive inotropes
NZ595770A (en) 2006-03-17 2013-04-26 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
WO2007120839A2 (en) 2006-04-13 2007-10-25 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
SG185255A1 (en) 2007-09-26 2012-11-29 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
EP3067352A3 (en) * 2008-05-07 2016-10-19 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
US20110160200A1 (en) 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
US20110144067A1 (en) * 2009-12-07 2011-06-16 Toscano John P N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives
MX356796B (es) 2009-12-07 2018-06-14 Cardioxyl Pharmaceuticals Inc Derivados de hidroxilamina bis-acilados.
BR112014009282B1 (pt) 2011-10-17 2021-12-14 The Johns Hopkins University Composto, composição farmacêutica contendo-o e uso do mesmo
EP2914579A1 (en) 2012-11-01 2015-09-09 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
HRP20182144T1 (hr) 2013-01-18 2019-03-08 Cardioxyl Pharmaceuticals Inc. Farmaceutske kompozicije koje sadrže donore nitroksila
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
KR102177899B1 (ko) 2020-11-12
SG11201505567RA (en) 2015-09-29
SG10201802855TA (en) 2018-05-30
EP2945620A1 (en) 2015-11-25
EP3284463B1 (en) 2019-07-24
ZA201604798B (en) 2018-01-31
BR112015017251B1 (pt) 2021-10-26
PL2945621T3 (pl) 2019-05-31
RS58174B1 (sr) 2019-03-29
AU2014207404A1 (en) 2015-08-13
US20190224159A1 (en) 2019-07-25
MX363843B (es) 2019-04-05
CN105073105B (zh) 2018-02-27
ZA201505090B (en) 2016-10-26
TWI712409B (zh) 2020-12-11
US11786501B2 (en) 2023-10-17
BR112015017241A8 (pt) 2019-10-29
IL239952A0 (en) 2015-08-31
US10792273B2 (en) 2020-10-06
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
CN105142627B (zh) 2019-06-21
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
LT3284463T (lt) 2019-11-11
KR20150107853A (ko) 2015-09-23
JP2017125015A (ja) 2017-07-20
CY1122177T1 (el) 2020-11-25
TW201934120A (zh) 2019-09-01
US9156804B2 (en) 2015-10-13
US20210015784A1 (en) 2021-01-21
PL3284463T3 (pl) 2019-12-31
NZ709986A (en) 2020-01-31
TW201442702A (zh) 2014-11-16
US20140206769A1 (en) 2014-07-24
CA2898445A1 (en) 2014-07-24
RU2015134581A (ru) 2017-02-27
US11304924B2 (en) 2022-04-19
AU2018203240B2 (en) 2019-12-12
BR112015017251A2 (pt) 2017-07-11
RU2015134583A (ru) 2017-02-22
SMT201800088T1 (it) 2018-03-08
HK1216857A1 (en) 2016-12-09
EP2945620B1 (en) 2017-11-22
SMT201900027T1 (it) 2019-02-28
IL239906A0 (en) 2015-08-31
DK2945621T3 (en) 2019-02-11
KR102277165B1 (ko) 2021-07-14
US20180235927A1 (en) 2018-08-23
AU2017200147B2 (en) 2018-07-05
HRP20180121T1 (hr) 2018-02-23
AU2014207408C1 (en) 2018-09-06
JP2019089764A (ja) 2019-06-13
LT2945621T (lt) 2019-01-10
DK3284463T3 (da) 2019-10-28
MX2015009269A (es) 2015-10-30
IL259233B (en) 2019-10-31
SI3284463T1 (sl) 2019-12-31
JP2019172682A (ja) 2019-10-10
WO2014113700A1 (en) 2014-07-24
IL239952B (en) 2018-05-31
SG10201913441RA (en) 2020-03-30
HUE036589T2 (hu) 2018-07-30
ES2705240T3 (es) 2019-03-22
AU2014207408A1 (en) 2015-08-13
SI2945621T1 (sl) 2019-01-31
AU2017200147A1 (en) 2017-02-02
CY1120535T1 (el) 2019-07-10
CN105142627A (zh) 2015-12-09
EP3567031A1 (en) 2019-11-13
CY1121480T1 (el) 2020-05-29
AU2014207404B2 (en) 2017-10-19
IL258882A (en) 2018-06-28
US20200163929A1 (en) 2020-05-28
US20170151210A1 (en) 2017-06-01
BR112015017251A8 (pt) 2019-10-29
HRP20191919T8 (hr) 2021-10-01
JP6656345B2 (ja) 2020-03-04
PT2945620T (pt) 2018-02-21
JP2016505044A (ja) 2016-02-18
MX2015009276A (es) 2015-10-30
TW201446242A (zh) 2014-12-16
IL259233A (en) 2018-07-31
CA2898443C (en) 2022-05-31
AU2018203240A1 (en) 2018-05-31
US11273143B2 (en) 2022-03-15
PL2945620T3 (pl) 2018-03-30
NZ709985A (en) 2020-05-29
JP2016510326A (ja) 2016-04-07
DK2945620T3 (en) 2018-02-05
CN108610312A (zh) 2018-10-02
HUE041861T2 (hu) 2019-06-28
TWI686193B (zh) 2020-03-01
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
US10213408B2 (en) 2019-02-26
PT3284463T (pt) 2019-10-30
ES2882279T3 (es) 2021-12-01
SG10201913286PA (en) 2020-02-27
SG10201802862WA (en) 2018-05-30
RU2684916C2 (ru) 2019-04-16
RU2676277C2 (ru) 2018-12-27
US20240066002A1 (en) 2024-02-29
EP3284463A1 (en) 2018-02-21
AU2014207408A8 (en) 2015-08-27
US10245249B2 (en) 2019-04-02
HK1251170B (en) 2020-04-09
CA2898445C (en) 2022-05-03
PT2945621T (pt) 2019-01-21
ES2751922T3 (es) 2020-04-02
CA2898443A1 (en) 2014-07-24
EP3427728B1 (en) 2021-07-07
ES2659969T3 (es) 2018-03-20
MX373176B (es) 2020-04-22
CN105073105A (zh) 2015-11-18
LT2945620T (lt) 2018-02-12
US20220193026A1 (en) 2022-06-23
AU2018241168A1 (en) 2018-11-01
TWI619491B (zh) 2018-04-01
IL239906B (en) 2018-05-31
EP3427728A1 (en) 2019-01-16
RS59434B1 (sr) 2019-11-29
JP6449171B2 (ja) 2019-01-09
HRP20191919T1 (hr) 2020-01-10
JP6311038B2 (ja) 2018-04-11
TR201802211T4 (tr) 2018-03-21
US20150175566A1 (en) 2015-06-25
US12186301B2 (en) 2025-01-07
JP6533159B2 (ja) 2019-06-19
HRP20182144T1 (hr) 2019-03-08
NZ748769A (en) 2020-05-29
JP6801045B2 (ja) 2020-12-16
BR112015017241A2 (pt) 2017-07-11
WO2014113696A1 (en) 2014-07-24
US9586896B2 (en) 2017-03-07
US8987326B2 (en) 2015-03-24
US10517847B2 (en) 2019-12-31
US10548872B2 (en) 2020-02-04
CN110179777B (zh) 2022-07-15
RU2018143994A (ru) 2019-01-16
AU2014207408B2 (en) 2018-03-01
CN110179777A (zh) 2019-08-30
BR112015017241B1 (pt) 2021-10-26
NZ748771A (en) 2019-12-20
SMT201900575T1 (it) 2019-11-13
KR20150108879A (ko) 2015-09-30
HK1216858A1 (en) 2016-12-09
WO2014113700A9 (en) 2014-10-09
US20190133990A1 (en) 2019-05-09
US9968584B2 (en) 2018-05-15
AU2018241168B2 (en) 2020-04-02
HUE046722T2 (hu) 2020-03-30

Similar Documents

Publication Publication Date Title
SI2945620T1 (en) Nitroxyl donors with improved therapeutic index
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015029972A2 (pt) composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
BR112018067930A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto.
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201490491A1 (ru) Производные 2-амино-4-(пиридин-2-ил)-5,6-дигидро-4h-1,3-оксазинов и их использование в качестве ингибиторов bace-1 и/или bace-2
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
MD20160078A2 (ro) Inhibitori ai Syk
EA201790088A1 (ru) Ингибиторы syk
JP2016510326A5 (OSRAM)
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
BR112015004523A2 (pt) compostos de tetraciclina
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
ME02405B (me) Spojevi pirazola као inhibitori sglt1
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
BR112015006243A2 (pt) agentes antibacterianos de fenicol
MX378409B (es) Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.